Reach Us +44-1647-403003
Rapid, Reliable, High Sensitivity Nucleic Acid Detection Technologies, Products And Services For Cancer Diagnosis And Therapy Monitoring | 99615
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Rapid, reliable, high sensitivity nucleic acid detection technologies, products and services for cancer diagnosis and therapy monitoring

Joint Event on 2nd International Conference on Cancer Biology, Therapeutics and Drug Discovery and Delivery & 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics

Michael J Powell

PhD. C.Chem, MRSC, DiaCarta Inc., USA

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C11-153

There is a demand for advanced technologies for the detection of circulating cell-free nucleic acids that can be implemented effectively and universally in the modern translational biology research laboratories and hospital pathology laboratories and clinical testing facilities worldwide. Especially as this relates to cancer detection, cancer therapy, and immunotherapy. This workshop will highlight the most recent developments in this field and how DiaCarta, Inc.'s proprietary technologies, products, and services can provide such a solution for the global monitoring of human disease diagnosis, progression, and therapy.

Michael J Powell is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, and business and corporate development. He has extensive knowledge and experience in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms. He has published many research papers in leading scientific journals and holds more than 40 patents and patent-pending applications. He received his PhD in medicinal organic chemistry from Loughborough University, Loughborough, UK and also pursued postdoctoral research and a teaching fellowship from the University of Nottingham, Nottingham, UK. He was also a postdoctoral industrial research fellow at the University of Oxford, UK and was instrumental in developing the amperometric glucose sensing technology that was the basis of Medisense, Inc. which was acquired by Abbott Labs for $950M.

E-mail: [email protected]


Relevant Topics